Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on February 04, 2019, 11:36:01 am
-
Gilead Sciences’ Epclusa (sofosbuvir/velpatasvir) is highly effective at treating hepatitis C virus (HCV) among those with genotype 3 of the virus and compensated cirrhosis (the milder form of the advanced liver disease). This is traditionally a hard population to treat.
Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco (The Liver Meeting), researchers pooled data from real-world cohorts from various nations. They excluded people with a history of decompensated cirrhosis (the more advanced form of the severe liver disease) or prior treatment with a hep C drug in the NS5A inhibitor class as well as those who were previously treated for HCV for longer than 12 weeks and were younger than 18 years old.
Read more...
https://www.hepmag.com/article/epclusa-high-cure-rate-genotype-3-hep-c-cirrhosis